$ACAD News
Last published 2d ago
- 2d agoACADAcadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent AppealBusiness WireSAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware’s May 2025 decision upholding Acadia’s U.S. Patent No. 11,452,721 (the ‘721 patent), which covers the NUPLAZID® (pimavanserin) 34 mg capsule formulation. “We ...
- 2d agoACADAcadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) ConferenceBusiness WireSAN DIEGO, Calif.--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026, in Boston. Acadia's presentations include an oral presentation featuring findings from the ...
- 1w agoACADACADIA PHARMACEUTICALS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoACADAcadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026Business WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 12:40 p.m. Greenwich Mean Time.A live
- 3w agoACADAcadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026Business WireCompany to host conference call and webcast on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report third quarter 2026 financial results
- 3w agoNTHINBIXACADAVXL+1Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar MarketGlobeNewswireNEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the disease for a short time. For
- 1mo agoACADAcadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041Business Wire-- The allowance strengthens the intellectual property portfolio for trofinetide and extends protections in the U.S. from July 2036 to March 2041 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the
- 1mo agoACADAcadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)Business Wire-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect -- Narrowly missed primary
- 2mo agoACADEuropean Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European UnionBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in
- 3mo agoACADAcadia Pharmaceuticals Reports Second Quarter 2026 Financial ResultsBusiness Wire- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP
- 3mo agoACADAcadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth ConferenceBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. Live
- 3mo agoACADAcadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease PsychosisBusiness Wire-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s disease psychosis, a serious condition with no FDA-approved therapies -- RADIANT Phase 2 enrollment completed, with
- 3mo agoACADAcadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026Business WireCompany to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report second quarter 2026 financial results on
- 4mo agoACADAcadia Pharmaceuticals Appoints Carl Segerstrom as Chief People OfficerBusiness Wire-- Experienced global HR leader joins Acadia to advance people strategy and support the next phase of growth Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Carl Segerstrom as Chief
- 4mo agoACADDAYBU® (trofinetide) Recommended for Approval in the European Union by CHMPBusiness Wire-- European Commission decision expected in the coming months -- If approved, DAYBU® would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc.
- 6mo agoACADAcadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial GuidanceBusiness Wire- First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway - First quarter NUPLAZID® GAAP net sales of $167 million, up 6% year-over-year on a
- 6mo agoACADAcadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished CareerBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed
- 6mo agoACADAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference Fireside Chat: Tuesday, May 12, 2026 at 4:20 p.m.
- 6mo agoACADAcadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual MeetingBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place
- 7mo agoACADAcadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026Business WireCompany to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on
- 7mo agoACADAcadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett SyndromeBusiness Wire-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for Rett syndrome and highlights the importance of flexible,
- 8mo agoACADAcadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS ForumBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of
- 8mo agoACADAcadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of DirectorsBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep
- 8mo agoACADAcadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett SyndromeBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally adopted a negative
- 8mo agoACADAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at
- 9mo agoACADAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026Business WireCompany to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report fourth quarter and full year 2025
- 9mo agoACADAcadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European UnionBusiness Wire- Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoption. Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that
- 10mo agoACADAcadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026Business WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the
- 11mo agoACADAcadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett SyndromeBusiness Wire-- DAYBUE STIX provides Rett syndrome patients and caregivers with new flexibility and choice in their treatment with DAYBUE -- DAYBUE and DAYBUE STIX are the only FDA-approved treatments for Rett syndrome, a rare
- 11mo agoACADAcadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare ConferenceBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast
- 1y agoACADAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 10, 2025 at 2:00 p.m. Eastern
- 1y agoLXEOMBRXACADGUTSBeyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat ConditionsPR NewswireEquity InsiderNews Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms,...
- 1y agoACADAcadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025Business WireCompany to host conference call and webcast on Wednesday, November 5, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report third quarter 2025 financial results
- 1y agoACADAcadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®Business WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson's Disease and Movement
- 1y agoACADAcadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary EndpointBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in
- 1y agoACADReal World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child NeurologyBusiness Wire-- Findings reinforce efficacy and tolerability profile in patients prescribed DAYBUE in the U.S. for as long as 12 months, consistent with the Phase 3 LAVENDER™ trial that supported FDA approval and open-label
- 1y agoACADAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on September 4, 2025, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified
- 1y agoACADACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoACADAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at three upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Monday, September 8,
- 1y agoACADAcadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy OfficerBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Konstantina ("Tina") Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia's business
- 1y agoACADAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on August 5, 2025, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock
- 1y agoACADACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoACADAcadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating OverviewBusiness Wire- Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE®
- 1y agoACADAcadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time. A live
- 1y agoACADAcadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data OfficerBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia's digital transformation
- 1y agoACADAcadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025Business WireCompany to host conference call and webcast on Wednesday, August 6, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report second quarter financial results on
- 1y agoACADAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock
- 1y agoACADAcadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value DriversBusiness WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the
- 1y agoACADAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock
- 1y agoACADU.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter PatentBusiness Wire- Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced